Browse studies, page 1082

Page 1082 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.

• Proteomic Signatures and Blood Adenosine Triphosphate Levels as Markers of Empagliflozin Efficacy in Type 2 Diabetes Mellitus and Heart Failure Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2025
• Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes British journal of clinical pharmacology, 2014
• Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus—A Narrative Review Healthcare, 2024
• A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches Advances in Therapy, 2022
• Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis Diabetes Therapy, 2019
• Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials Diabetes Research and Clinical Practice, 2018
• SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials The Lancet, 2022
• Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes Diabetes & Metabolic Syndrome Clinical Research & Reviews, 2022
• The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews Endocrinology Diabetes & Metabolism, 2020
• Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis European Journal of Preventive Cardiology, 2021
• Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors Diabetes and Vascular Disease Research, 2021
• Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews Therapeutic Advances in Drug Safety, 2021
• Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials Frontiers in Endocrinology, 2022
• Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis Saudi Journal of Biological Sciences, 2018
• Association of SGLT2 Inhibitors with Arrhythmias and Sudden Cardiac Death in Patients with Type 2 Diabetes or Heart Failure: A Meta-Analysis of 34 Randomized Controlled Trials Heart Rhythm, 2021
• Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review Advances in Therapy, 2021
• Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis Diabetology & Metabolic Syndrome, 2015
• Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials Metabolites, 2020
• SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials Diabetologia, 2017
• Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Heart Failure Reviews, 2020
• SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis BMJ Open, 2016
• Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons Diabetes Therapy, 2018
• Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide - a review International journal of retina and vitreous, 2026
• Plain language summary of a publication: the effects of vicadrostat given with or without empagliflozin for treatment of chronic kidney disease Sage open chronic disease, 2026
• Role of Sodium-Glucose Transport Protein-2 Inhibitors in Renal Protection: A Narrative Review from the Cardiovascular-Kidney-Metabolic Interconnection Drug design, development and therapy, 2026
• Nephrology: What You May Have Missed in 2025 Annals of internal medicine, 2026
• Sodium-Glucose Cotransporter-2 Inhibitors in Anthracycline-Treated Cancer Patients: A Narrative Review of Emerging Cardioprotective Evidence Cureus, 2026
• Which aldosterone antagonist? Choosing between sprionolactone and the novel drug finerenone Nederlands tijdschrift voor geneeskunde, 2026
• Food-drug interactions of novel drugs used in cardiologic and diabetic patients - a PRISMA scoping review Frontiers in pharmacology, 2026
• Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Liver Cirrhosis: A Systematic Review and Meta-Analysis Cureus, 2026
• Cardiac Troponin Elevation Beyond Type 1 Myocardial Infarction: A Systematic Review of Prognostic Significance and Cardiovascular Risk Stratification Cureus, 2026
• Effectiveness of SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Integrative Review of Reviews and Comparative Effectiveness Studies (2020-2025) Pharmacy (Basel, Switzerland), 2026
• SGLT2 inhibitors as modulators of mitochondrial ion transport and ER-mitochondria cross talk in diabetic cardiomyopathy American journal of physiology. Cell physiology, 2026
• Integrated Management Strategies for Hypertension and Diabetes in Cardiovascular Disease Prevention: A Systematic Review Cureus, 2026
• Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A Systematic Review Medical journal of the Islamic Republic of Iran, 2025
• Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis American journal of therapeutics, 2026
• SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026
• Sodium-Glucose Cotransporter-2 Inhibitors in Mood Disorders: A Narrative Review of Mechanisms, Evidence, and Challenges Neuropsychiatric disease and treatment, 2026
• Advances in targeted treatment of ferroptosis in diabetic kidney disease with SGLT2 inhibitors Diabetology & metabolic syndrome, 2026
• SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications Journal of clinical medicine, 2026
• From molecules to the clinic-pathophysiology of sodium-glucose cotransporter 2 inhibitors and their emerging role in urology: A comprehensive review from the European Association of Urology Section of Endourology Asian journal of urology, 2026
• Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome Frontiers in pharmacology, 2026
• Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence Frontiers in cardiovascular medicine, 2026
• Mechanisms and Therapeutic Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Reviews in cardiovascular medicine, 2026
• The Effects of New Antidiabetic Drugs on the Course of Peripheral Arterial Occlusive Disease Deutsches Arzteblatt international, 2026
• Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors Pharmacology & therapeutics, 2026
• Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: From Metabolic Mechanisms to International Guidelines Antioxidants (Basel, Switzerland), 2026
• Association between metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction Przeglad gastroenterologiczny, 2026
• Metabolic Dysfunction-Associated Steatotic Liver Disease and Mitochondrial Quality Control: From Laboratory to Clinical Practice Frontiers in bioscience (Landmark edition), 2026
• Late INa as a Therapeutic Target: New Strategies, Computational Modelling, Drug Development, and Clinical Translation Medicinal research reviews, 2026
• SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review International journal of molecular sciences, 2026
• SGLT2 Inhibitors in Alzheimer's Disease: Biochemical Insights and Therapeutic Potential International journal of molecular sciences, 2026
• Repurposing Heart Failure Therapies in Pulmonary Arterial Hypertension: Mechanistic Rationale, Translational Evidence, and Clinical Perspectives for SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists Medicina (Kaunas, Lithuania), 2026
• Evaluation of the therapeutic effect of new hypoglycemic drugs on patients with heart failure with reduced ejection fraction and type 2 diabetes: a systematic review and network meta-analysis Frontiers in cardiovascular medicine, 2026
• Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023-2025 Heart, lung & circulation, 2026
• Effect of sodium-glucose cotransporter-2 inhibitors on electrocardiographic markers of ventricular repolarization: A systematic review and meta-analysis American heart journal plus : cardiology research and practice, 2026
• Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis Cardiorenal medicine, 2026
• Continuous Infusion and Sequential Nephron Blockade Versus Bolus Furosemide in Acute Heart Failure: A Systematic Review Cureus, 2026
• Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis Frontiers in pharmacology, 2026
• The Potential Roles of Oral Hypoglycemic Agents to Modulate Mitochondrial Function in Type 1 Diabetes Mellitus: A Scoping Review Life (Basel, Switzerland), 2026
• Comparative Effects of Heart Failure Medications on Cardiac Remodeling via the Hydrogen Sulfide (H2S) Pathway: A Systematic Review Diseases (Basel, Switzerland), 2026
• Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Left Ventricular Global Longitudinal Strain in Adults with Type 2 Diabetes Mellitus: A Systematic Review Journal of clinical medicine, 2026
• A Review of the Current Literature Regarding Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Preserved Ejection Fraction and Timing of Initiating Therapy Cureus, 2026
• New therapies for the treatment of heart failure with preserved ejection fraction American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022
• Nonproteinuric progressive diabetic kidney disease Current opinion in nephrology and hypertension, 2019
• An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option Expert opinion on pharmacotherapy, 2020
• Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis Frontiers in pharmacology, 2022
• Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici World journal of cardiology, 2024
• ALDH2 Enzyme Deficiency in Diabetic Cardiomyopathy International journal of molecular sciences, 2025
• Clinical pharmacology of SGLT-2 inhibitors in heart failure Expert review of clinical pharmacology, 2023
• The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions Heart failure reviews, 2018
• SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review Journal of clinical medicine, 2022
• Comparative Pharmacological and Pharmaceutical Perspectives on Antidiabetic Therapies in Humans, Dogs, and Cats Pharmaceutics, 2025
• The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes Canadian journal of diabetes, 2017
• Efficacy of Sodium-Glucose 2 Transporter Inhibitors in Heart Failure With Preserved Ejection Fraction: A Narrative Review Cureus, 2024
• Mineral and Electrolyte Disorders With SGLT2i Therapy JBMR plus, 2019
• The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure US cardiology, 2025
• Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease Diabetes therapy : research, treatment and education of diabetes and related disorders, 2016
• Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus Indian heart journal, 2018
• Antihyperglycemic agents and cardiovascular outcomes: recent insights Current opinion in cardiology, 2017
• Advances in GLP-1 treatment: focus on oral semaglutide Diabetology & metabolic syndrome, 2021
• Current Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction Cardiovascular & hematological disorders drug targets, 2022
• The effect of sodium-glucose cotransporter type 2 inhibitors on left ventricular diastolic function: current status and prospects Kardiologiia, 2024
• Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients Cureus, 2021
• Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? Therapeutic advances in endocrinology and metabolism, 2022
• Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i Current vascular pharmacology, 2021
• Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review Cureus, 2024
• Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes International journal of clinical practice, 2015
• Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus European heart journal, 2016
• The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies Expert opinion on drug safety, 2018
• Optimizing management of glycaemia Best practice & research. Clinical endocrinology & metabolism, 2016
• Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020
• Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope Diabetes, obesity & metabolism, 2019
• Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer? European journal of clinical investigation, 2024
• Diabetology as an interdisciplinary challenge Der Internist, 2017
• Pharmacological management of type 2 diabetes: what's new in 2017? Expert review of clinical pharmacology, 2017
• Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients Cardiovascular diabetology, 2021
• Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis Diabetes, obesity & metabolism, 2026
• Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis Frontiers in pharmacology, 2023
• Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased Der Internist, 2017